B Cell based Cross Blocking Assay Service

Creative Biolabs' B cell-based cross blocking assay delivers a clear, quantitative measure of functional equivalence, a critical step in de-risking your therapeutic program. We provide a solution that is deeply rooted in physiological relevance, offering an unparalleled level of confidence in your data. Our service is designed to seamlessly integrate into your workflow, helping you accelerate drug discovery and develop highly specific antibodies through an innovative cell-based screening platform.

Antibody-mediated Blocking Assay

If an antibody binds to an antigen and blocks other antibodies or receptor proteins from binding to the antigen, it is called a blocking antibody. Therefore, a blocking assay is also called an antibody competition assay. Cross blocking assays are usually used for antibody classification based on epitope specificity. The blocking function is also applied to control allergic disorders. Therefore, cross blocking assay is functional to identify human monoclonal antibodies with broad and synergistic neutralizing functions against various infections.

Discover how we can help - Request a consultation.

What We Can Offer

• The competition ELISA assay
  The peptides are immobilized on the plate, and the first native unlabeled mAbs/receptors are added to the plate at saturating titers. Next, the other labeled mAbs diluted to serial concentrations are added to the same wells. After inoculation, the peptide-labeled mAbs complex is detected by a color reaction. The blocking rate is calculated by comparing OD in the presence and absence of competitor mAbs.

Fig.1 Illustration of the competitive ELISA assay for cross blocking. ^{1, 4}

• The classical sandwich ELISA-based cross-blocking assay.

Fig.2 Applying classical sandwich ELISA for cross block assay. ^{2, 4}

• Mixing mAbs with an epitope protein probe at a specific ratio.
  The blocking rate can also be conducted by inoculating with epitope protein-expressing cells to compete for binding and measured by cell image.
• Blocking the receptor to the epitope ligand.

Cross Blocking Assay Services at Creative Biolabs

Fig.3 Isolate antigen-reactive antibodies from the recovered patients. ^{3, 4}

Highlights

True-to-Life Data

Our assay directly measures antibody binding to native receptors on living B cells. This provides a more accurate prediction of in vivo behavior, giving you confidence in the safety and efficacy of your therapeutic.

High-Fidelity Epitope Mapping

We detect subtle epitope binding differences that traditional assays often miss. This high specificity helps you minimize the risk of late-stage failures and unexpected immunogenicity, saving you time and resources.

Actionable Data Insights

We don't just deliver raw data. Our final reports include expert analysis and interpretation, providing you with actionable insights that accelerate decision-making. This enables you to confidently advance your therapeutic program.

Consistent, Reliable Results

Our standardized platform and stringent quality controls ensure highly consistent and reproducible results. This rigorous approach reduces data variability and provides unwavering confidence, allowing you to focus on your project's next steps.

Discover how a partnership with us can streamline your research - Get a quote today.

Customer Reviews

• Preventing Costly Failures
  The precision of the B cell-based cross blocking assay allowed us to confidently distinguish between two different antibody variants that looked identical in a conventional ELISA, preventing a costly failure later in the development process. - C. G*on, Senior Researcher.
• Validating Biosimilarity
  Using Creative Biolabs' B cell-based cross blocking assay in our research has significantly improved our ability to validate the functional similarity of our biosimilar candidates. - S. P*er, Project Manager.

FAQs

Related Services

How to Contact Us

With the versatile blocking assay, it is efficient to identify the minimal epitope sequence of a conformational B-cell epitope and identify an immunodominant epitope within a protein antigen. Creative Biolabs provides a variety of blocking antibodies and tailored blocking assays to meet your special demands. To learn more, please contact us for more detailed information.

References

1. Li, Yuan et al. "Development and evaluation of a monoclonal antibody-based competitive ELISA for the detection of antibodies against H7 avian influenza virus." BMC veterinary research vol. 17,1 64. 2 Feb. 2021. https://doi.org/10.1186/s12917-021-02772-6
2. Abdiche, Yasmina Noubia et al. "Antibodies Targeting Closely Adjacent or Minimally Overlapping Epitopes Can Displace One Another." PloS one vol. 12,1 e0169535. 6 Jan. 2017. https://doi.org/10.1371/journal.pone.0169535
3. Chen, Xiangyu et al. "Human monoclonal antibodies block the binding of SARS-CoV-2 spike protein to angiotensin converting enzyme 2 receptor." Cellular & molecular immunology vol. 17,6 (2020): 647-649. https://doi.org/10.1038/s41423-020-0426-7
4. Distributed under an Open Access license CC BY 4.0, without modification.

For Research Use Only | Not For Clinical Use